Now showing items 1-16 of 16

      Financiación
      Angelini Pharma Espana SLU [1]
      Bial Group [1]
      ERDF A way of making Europe [1]
      MCIN/AEI PID2021-129042OA-I00 [1]
      Ministry of Universities, Spain FPU20/02400 [1]
      Spanish Ministry of Economy, Industry and Competitiveness, Instituto Carlos III (FIS PI20/01657). [1]
      The authors acknowledge Lorraine Maw, MA, at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA, who helped in editing this article. The authors also acknowledge the reviewers who helped them to improve this article. [1]
      The source of funding that has supported the work is European Fund of Regional Development (FEDER-BFU2008-05340). [1]
      This research was funded by grant P07-SEJ-02964 from Junta de Andalucía (Spain). [1]
      This study has been funded by grants PSI2010-17290 (INTEROBE) from the Ministry of Innovation and Science (MICINN), and P-10-HUM-6635 (NEUROECOBE). [1]
      This study was funded by the Medical Research Council, UK. GlaxoSmithKline (G0701420) funded the DeNT study and were co-funders with the Medical Research Centre for the GWAS of the whole sample. The GENDEP study was funded by a European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT- 2003-503428. This study presents independent research [part-] funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The CoLaus/PsyCoLaus was funded by four grants from the Swiss National Science Foundation (#32003B-105993, #32003B-118308, #33CSC0-122661, and #139468), the Faculty of Biology and Medicine of Lausanne, and two grants from GlaxoSmithKline Clinical Genetics. [1]
      This study was partially funded by grants from the Fondo de Investigaciones Sanitarias Instituto de Salud Carlos III, Ministry of economy and competitivity (Project No. FIS PI021813 and FIS PF09/01671), and by Proyecto de Excelencia, Consejeria de Innovacion, Junta de Andalucia (Project No. CTS 1686). [1]
      This study was supported by grants from the National Institutes of Health (NIH) grant no. 1 R01 DA017987, Grant 2005SGR00032, Fondo de Investigaciones Sanitarias (FIS-00/00777), Plan Nacional Sobre Drogas (INT/2012/2002) Spain, Plan Nacional Sobre Drogas: PNSD 2006/101(2007–2009) Spain. [1]
      This work was supported by the National Institutes for Neurological Disorders and Stroke (NINDS, DA19959, to TJP), the American Pain Society (to TJP), the Spanish Secretaria de Estado de Educacion y Universidades: Formacion de Profesorado Universitario Grant (to JME), the Canadian Foundation for Innovation (CFI, to FC), the Canadian Institutes of Health Research (CIHR, to FC) and the Fonds de la recherche en santé du Québec (FRSQ, to FC). [1]
      Universidad de Granada/CBUA [1]
      We thank the BBSRC, MRC and Wellcome Trust for their generous support. We also thank Dr. Ruediger Klein for supplying the floxed exon 2 ephrin-B2 mouse line. CMC was supported by the Research Program of the University of Granada. [1]